Company intelligence / Profile preview
Novatek Pharmaceuticals
Houston, Texas, United Statesnovatekpharmaceuticals.com ↗
- Ownership
- Private
- Employees
- ~500
- Development stage
- Other
01
Overview
Novatek Pharmaceuticals is developing NP‑101, a naturally derived immunomodulator from black seed oil. Clinical trials have shown significant effects on T cell populations in cancer patients. A small randomized Phase II trial in outpatient COVID-19 has been published; a larger Phase IIb trial is ongoing. Oncology trials are underway for high-grade neuroendocrine cancers and additional cancer types are planned or enrolling.[10]
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small molecules (notably thymoquinone, derived from Nigella Sativa/black seed oil)[1][4][10]Immunomodulatory agents[1][4]
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Novatek Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novatek Pharmaceuticals.